144 results
424B5
PCSA
Processa Pharmaceuticals Inc
28 May 24
Prospectus supplement for primary offering
4:49pm
the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and 2022 have been audited by BD & Company, Inc., an independent registered … appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, have been audited by BD & Company, Inc., an independent
8-K
EX-4.2
puisp7yt saa02
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-10.1
jrdl 8hwr1cl
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-4.3
1n7y hrorxm
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
8-K
EX-4.1
joslngp4u3
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
424B4
smt 0ss4s2
29 Jan 24
Prospectus supplement with pricing info
4:15pm